San Diego-based biotech Receptos has priced an initial public offering of 5.2 million shares at $14, raising $72.8 million as the company closes in on late-stage development of its lead candidate for multiple sclerosis.
What happens when a new drug comes charging out of the launch gate? For Biogen Idec, it means a rethink of its real estate plans.
When George Scangos took the helm at Biogen Idec, he left little doubt that he couldn't much stand the company's gleaming new headquarters in Weston, MA, the brainchild of ex-CEO Jim Mullen. R&D in Cambridge was where it was at, and that's where he spent the bulk of his time.
Teva Pharmaceutical Industries may be a generics behemoth, but its earnings this quarter bore a more-than-casual resemblance to Big Pharma's.
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.
Biogen Idec CEO George Scangos took home one of the largest pay packages in the biotech industry in 2012--a total of $13.45 million in 2012, a 19% jump in pay from his $11.33 million pay package the previous year, the Weston, MA-based company reported Monday in a proxy statement.
After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
Fujifilm has opened a cell-banking facility at the former Merck plant in Billingham, U.K., and is also expanding its mammalian cell manufacturing capacity.
A new analysis shows that the biggest biotech players have outperformed a group of pharma giants over the previous three years, with the value of the biotech group up 57% compared with 17.4% growth in the pharma camp.
Royalty Pharma has brought a fully financed offer for Elan to the table, poking a hole in the argument from Elan management about the bidder's ability to make a credible offer. On Monday Royalty rolled out an offer of up to $12 per share, upping the ante from the investment group's previous overture.